Probiotix Health PLC New commercial partnership agreement in China

RNS Number : 4799A

Probiotix Health PLC

15 August 2024

 

15 August 2024

ProBiotix Health plc

("ProBiotix" or the "Company")

 

New commercial partnership agreement in China

                                                                                                   

ProBiotix Health plc (AQUIS: PBX), a life sciences business developing probiotics to support cardiometabolic health, announces a new commercial partnership agreement for InstaMelt with DanCare Health homepage - Dancarehealth). InstaMelt is ProBiotix's newly developed food supplement dosage format that offers innovative features for health brands and retailers. It will be sold as a turnkey, direct dose stick solution that melts instantly on the tongue and will be available in China through DanCare Health. InstaMelt will be launched during Q4 2024 under the DanCare brand and represents a key milestone in the Company's efforts to penetrate the Chinese market with cardiometabolic supplement solutions containing the IP-protected probiotic strain LP_LDL®.

 

DanCare Health was founded in Denmark in 2003, with an initial focus on supplying high quality branded products to the European supplement industry. DanCare has since developed into a global organisation having expanded well into China as one of their strongholds taking off-set in their European manufactured quality products. DanCare offers a broad range of clinically documented, high quality supplements all marketed globally under the company's DanCare brand.

 

Steen Andersen, CEO of ProBiotix Health plc, commented: "DanCare is well-recognised in the Chinese market as a high-quality innovative brand. With cardiovascular disease on the rise and almost 155 million Chinese adults estimated to have elevated cholesterol levels, there is an increasing consumer focus on cardiometabolic health. With our product offering and cooperation with a market leader like DanCare we are well positioned to tap into this lucrative market over the years to come."

 

The CEO and spokesperson of DanCare Health commented: "We are looking forward to this collaboration with ProBiotix Health as our two companies share the same vision of improving quality of life by bringing efficacious, high quality innovate supplements to market. The significant clinical documentation backing the strain LP_LDL®, in combination with the innovative new stick dosage format and DanCare Health's strong market position, will be an excellent addition to our product line in the Chinese market. This sets high growth expectations for the product. We are excited to see where this dynamic partnership leads."

 

For further information, please contact:

 

ProBiotix Health plc	https://probiotixhealth-ir.com/
Steen Andersen, Chief Executive	Contact via Walbrook below
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker)	Tel: [phone]
Mark Anwyl
Duncan Vasey
Walbrook PR Ltd	[e-mail]
Anna Dunphy	Mob: [phone]

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXBXGDIDUBDGSS